Blood Screening Market Analysis By Technology, By Product And Segment Forecasts, 2013 - 2024

  • ID: 3989858
  • Report
  • 90 pages
  • Grand View Research
1 of 3
The global blood screening market is expected to reach a value of USD 3.9 billion by 2024. The growth of the market is attributed to the increasing screening of donor and continuous technological advancements by the market players. Demand for blood screening tests are increasing continuously due to increasing donation, rising awareness about transfusion-transmitted diseases, and technological developments in the industry.

Thorough screening is necessary for all donated blood to ensure that recipients receive the safest products. As of 2015, such testing consists of screening for red cell antibodies, and the infectious diseases agents: HIV-1, HIV-2, hepatitis virus, West Nile Virus (WNV), Human T-Lymphotropic Virus (HTLV) T. Cruzi, and T. pallidum (syphilis). Result of all these assays must be negative for blood donation.

Technological developments in the market increase the sensitivity and efficiency of the tests. For instance, in 2016, the U.S. FDA approved the Procleix Zika virus assay from Hologic, Inc. and Grifols to screen donated blood. Furthermore, the U.S. FDA approved next-generation sequencing (NGS) technology in 2013. The technology is cheaper and faster than previous DNA analysis methods.

Further Key Findings from the Study Suggest:

Nucleic acid amplification test or nucleic acid test (NAT) is expected to be the fastest growing segment during the forecast period. It comprises transcription mediated amplification (TMA) tests and polymerase chain reaction. Increasing demand of NAT over ELISA test due to high sensitivity and specificity for viral nucleic acid is contributing to the fastest growth during the forecast period.

In 2015, reagent dominated the product segment. Introduction of new assays for the detection of various diseases is expected to enable the segment to gain the maximum share of market in the coming years. For instance, in January 2015 the FDA approved Roche’s blood screening assay COBAS TaqScreen MPX Test for the detection and identification of HCV, HIV, and HBV.

In 2015, regionally North America dominated with a revenue share of more than 40%. Government initiatives, presence of major players, and more patient affordability are the major factors that contributed toward its dominance.

In August 2016, the FDA recommended the testing of all the donated blood in the U.S. and its territories for Zika virus in order to prevent transmission of this virus through the blood supply.

Asia Pacific is expected to be the fastest growing region due to increasing investment of industry players, government initiatives, and rising awareness about transmission of diseases during its transfusion.

The Red Cross in Japan entered into a contract with Grifols for nucleic acid testing (NAT) for a blood donation camp in Japan in 2014. This agreement is anticipated to propel the NAT market during the forecast period. However, low donation as compared to requirement and high cost of kits and instruments are likely to restrain the growth in low-income countries during the forecast period.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1 Research Methodology
1.1 Information Procurement
1.2 Data Analysis
2 Executive Summary
2.1 Market Snapshot
3 Market Variables, Trends & Scope
3.1 Market Segmentation and Scope
3.1.1 Market driver analysis
3.1.1.1 Increasing donor screening
3.1.1.2 Increasing Government Initiatives
3.1.1.3 Technological Developments
3.1.2 Market restraint analysis
3.1.2.1 High Cost
3.2 Penetration & Growth Prospects Mapping
3.3 Blood Screening Market - PESTLE Analysis
3.4 Industry Analysis - Porter’s
3.5 Blood screening competitive scenario, 2015
3.5.1 Competitive landscape: Market position analysis (based on products, regional presence and strategic initiatives)
4 Blood Screening Market Technology Estimates & Trend Analysis
4.1 Blood Screening Market: Technology Movement Analysis
4.2 Nucleic Acid Amplification Test (NAT)
4.2.1 Nucleic Acid Amplification Test (NAT) market estimates and forecasts, 2013 - 2024 (USD Million)
4.3 ELISA
4.3.1 ELISA market estimates and forecasts, 2013 - 2024 (USD Million)
4.4 Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
4.4.1 Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA) market estimates and forecasts, 2013 - 2024 (USD Million)
4.5 Next-Generation Sequencing (NGS)
4.5.1 Next-generation sequencing (NGS) market estimates and forecasts, 2013 - 2024 (USD Million)
4.6 Western Blotting
4.6.1 Western blotting market estimates and forecasts, 2013 - 2024 (USD Million)
5 Blood Screening Market Product Estimates & Trend Analysis
5.1 Blood Screening Market: Product Movement Analysis
5.2 Reagent
5.2.1 Reagent market estimates and forecasts, 2013 - 2024 (USD Million)
5.3 Instrument
5.3.1 Instrument market estimates and forecasts, 2013 - 2024 (USD Million)
6 Blood Screening Market Regional Estimates & Trend Analysis
6.1 Regional Movement Analysis & Market Share, 2015 & 2024
6.2 North America
6.2.1 North America blood screening market, by technology, 2013 - 2024 (USD Million)
6.2.2 North America blood screening market, by product, 2013 - 2024 (USD Million)
6.2.3 U.S.
6.2.3.1 U.S. blood screening market, by technology, 2013 - 2024 (USD Million)
6.2.3.2 U.S. blood screening market, by product, 2013 - 2024 (USD Million)
6.2.4 Canada
6.2.4.1 Canada blood screening market, by technology, 2013 - 2024 (USD Million)
6.2.4.2 Canada blood screening market, by product, 2013 - 2024 (USD Million)
6.3 Europe
6.3.1 Europe blood screening market, by technology, 2013 - 2024 (USD Million)
6.3.2 Europe blood screening market, by product, 2013 - 2024 (USD Million)
6.3.3 Germany
6.3.3.1 Germany blood screening market, by technology, 2013 - 2024 (USD Million)
6.3.3.2 Germany blood screening market, by product, 2013 - 2024 (USD Million)
6.3.4 UK
6.3.4.1 UK blood screening market, by technology, 2013 - 2024 (USD Million)
6.3.4.2 UK blood screening market, by product, 2013 - 2024 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific blood screening market, by technology, 2013 - 2024 (USD Million)
6.4.2 Asia Pacific blood screening market, by product, 2013 - 2024 (USD Million)
6.4.3 Japan
6.4.3.1 Japan blood screening market, by technology, 2013 - 2024 (USD Million)
6.4.3.2 Japan blood screening market, by product, 2013 - 2024 (USD Million)
6.4.4 China
6.4.4.1 China blood screening market, by technology, 2013 - 2024 (USD Million)
6.4.4.2 China blood screening market, by product, 2013 - 2024 (USD Million)
6.4.5 India
6.4.5.1 China blood screening market, by technology, 2013 - 2024 (USD Million)
6.4.5.2 China blood screening market, by product, 2013 - 2024 (USD Million)
6.5 Latin America
6.5.1 Latin America blood screening market, by technology, 2013 - 2024 (USD Million)
6.5.2 Latin America blood screening market, by product, 2013 - 2024 (USD Million)
6.5.3 Brazil
6.5.3.1 Brazil blood screening market, by technology, 2013 - 2024 (USD Million)
6.5.3.2 Brazil blood screening market, by product, 2013 - 2024 (USD Million)
6.5.4 Mexico
6.5.4.1 Mexico blood screening market, by technology, 2013 - 2024 (USD Million)
6.5.4.2 Mexico blood screening market, by product, 2013 - 2024 (USD Million)
6.6 MEA
6.6.1 MEA blood screening market, by technology, 2013 - 2024 (USD Million)
6.6.2 MEA blood screening market, by product, 2013 - 2024 (USD Million)
6.6.3 South Africa
6.6.3.1 South Africa blood screening market, by technology, 2013 - 2024 (USD Million)
6.6.3.2 South Africa blood screening market, by product, 2013 - 2024 (USD Million)
7 Competitive Landscape
7.1 Abbott Laboratories
7.1.1 Company overview
7.1.2 Financial performance
7.1.3 Product benchmarking
7.1.4 Strategic initiatives
7.2 Danaher Corporation (Beckman Coulter)
7.2.1 Company overview
7.2.2 Financial performance
7.2.3 Product benchmarking
7.2.4 Strategic initiatives
7.3 Becton Dickinson and Company
7.3.1 Company overview
7.3.2 Financial performance
7.3.3 Product benchmarking
7.3.4 Strategic initiatives
7.4 Bio-Rad Laboratories, Inc.
7.4.1 Company overview
7.4.2 Financial performance
7.4.3 Product benchmarking
7.4.4 Strategic initiatives
7.5 F. Hoffmann-La Roche Ltd.
7.5.1 Company overview
7.5.2 Financial performance
7.5.3 Product benchmarking
7.5.4 Strategic initiatives
7.6 Grifols
7.6.1 Company overview
7.6.2 Financial performance
7.6.3 Product benchmarking
7.6.4 Strategic Initiatives
7.7 Ortho-Clinical Diagnostics, Inc.
7.7.1 Company overview
7.7.2 Financial performance
7.7.3 Product benchmarking
7.7.4 Strategic initiatives
7.8 SOFINA s.a (Biomérieux)
7.8.1 Company overview
7.8.2 Financial performance
7.8.3 Product benchmarking
7.8.4 Strategic initiatives
7.9 Siemens Healthcare GmbH
7.8.1 Company overview
7.8.2 Financial performance
7.8.3 Product benchmarking
7.8.4 Strategic initiatives
7.10 Thermo Fisher Scientific, Inc
7.10.1 Company overview
7.10.2 Financial performance
7.10.3 Product benchmarking
7.10.4 Strategic initiatives

List of Tables

Table 1 Blood screening market - global market current and forecast by regions (2015-2024) in (USD Million)
Table 2 North America blood screening market estimates and forecasts, by country, 2013 - 2024 (USD Million)
Table 3 North America blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
Table 4 North America blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
Table 5 U.S. blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
Table 6 U.S. blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
Table 7 Canada blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
Table 8 Canada blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
Table 9 Europe blood screening market estimates and forecasts, by country, 2013 - 2024 (USD Million)
Table 10 Europe blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
Table 11 Europe blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
Table 12 UK blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
Table 13 UK blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
Table 14 Germany blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
Table 15 Germany blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
Table 16 Asia Pacific blood screening market estimates and forecasts, by region, 2013 - 2024 (USD Million)
Table 17 Asia Pacific blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
Table 18 Asia Pacific blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
Table 19 Japan blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
Table 20 Japan blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
Table 21 China blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
Table 22 China blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
Table 23 India blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
Table 24 India blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
Table 25 Latin America blood screening market estimates and forecasts, by country, 2013 - 2024 (USD Million)
Table 26 Latin America blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
Table 27 Latin America blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
Table 28 Brazil blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
Table 29 Brazil blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
Table 30 Mexico blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
Table 31 Mexico blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
Table 32 MEA blood screening market estimates and forecasts, by country, 2013 - 2024 (USD Million)
Table 33 MEA blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
Table 34 MEA blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)
Table 35 South Africa blood screening market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
Table 36 South Africa blood screening market estimates and forecasts, by product, 2013 - 2024 (USD Million)

List of Figures

Figure 1 Market research process
Figure 2 Information procurement
Figure 3 Primary research pattern
Figure 4 Market research approaches
Figure 5 Value chain based sizing & Forecasting
Figure 6 QFD modeling for market share assessment
Figure 7 Market summary
Figure 8 Market trends & outlook
Figure 9 Market segmentation & scope
Figure 10 Market driver relevance analysis (Current & future impact)
Figure 11 Market restraint relevance analysis (Current & future impact)
Figure 12 Penetration & growth prospect mapping
Figure 13 Blood screening market - PESTLE analysis
Figure 14 Porter’s Five Forces Analysis
Figure 15 Blood screening market outlook key takeaways
Figure 16 Blood screening market: Technology movement analysis
Figure 17 Global blood screening market, by technology 2013 - 2024 (USD Million)
Figure 18 Global blood screening market, 2013 - 2024 (USD Million)
Figure 19 Global Nucleic Acid Amplification Test (NAT) market, 2013 - 2024 (USD Million)
Figure 20 Global ELISA market, 2013 - 2024 (USD Million)
Figure 21 Global Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA) market, 2013 - 2024 (USD Million)
Figure 22 Global Next-Generation Sequencing (NGS) market, 2013 - 2024 (USD Million)
Figure 23 Global western blotting market, 2013 - 2024 (USD Million)
Figure 24 Blood screening market: Product movement analysis
Figure 25 Global blood screening market, by technology 2013 - 2024 (USD Million)
Figure 26 Global Reagent market, 2013 - 2024 (USD Million)
Figure 27 Global Instrument market, 2013 - 2024 (USD Million)
Figure 28 Regional market place: Key takeaways
Figure 29 Blood screening market regional outlook, 2015 & 2024
Figure 30 North America blood screening market, 2013 - 2024 (USD Million)
Figure 31 U.S. blood screening market, 2013 - 2024 (USD Million)
Figure 32 Canada blood screening market, 2013 - 2024 (USD Million)
Figure 33 Europe blood screening market, 2013 - 2024 (USD Million)
Figure 34 Germany blood screening market, 2013 - 2024 (USD Million)
Figure 35 UK blood screening market, 2013 - 2024 (USD Million)
Figure 36 Asia Pacific blood screening market, 2013 - 2024 (USD Million)
Figure 37 Japan blood screening market, 2013 - 2024 (USD Million)
Figure 38 China blood screening market, 2013 - 2024 (USD Million)
Figure 39 India blood screening market, 2013 - 2024 (USD Million)
Figure 40 Latin America blood screening market, 2013 - 2024 (USD Million)
Figure 41 Brazil blood screening market, 2013 - 2024 (USD Million)
Figure 42 Mexico blood screening market, 2013 - 2024 (USD Million)
Figure 43 Middle East Africa blood screening market, 2013 - 2024 (USD Million)
Figure 44 South Africa blood screening market, 2013 - 2024 (USD Million)
Figure 45 Strategy frameworks
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll